Share on StockTwits

Analysts at William Blair began coverage on shares of Vital Therapies (NYSE:VTL) in a research report issued to clients and investors on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.

Vital Therapies (NYSE:VTL) opened at 12.50 on Monday. Vital Therapies has a 52-week low of $10.66 and a 52-week high of $13.00. The stock’s 50-day moving average is $12.27 and its 200-day moving average is $12.27. The company’s market cap is $263.9 million.

Separately, analysts at Credit Suisse initiated coverage on shares of Vital Therapies in a research note on Monday. They set an “outperform” rating on the stock.

Vital Therapies, Inc is a biotherapeutic company. The Company focused on developing a cell-based therapy targeting the treatment of all forms of acute liver failure.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.